Udpglucose 4 Epimerase Deficiency C0751161
A rare metabolic disorder affecting how the body processes certain sugars. Treatment involves strict dietary restrictions to avoid toxic buildup of galactose-derived compounds.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Cataracts
(metabolic)Fatigue or weight changes
(metabolic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Hepatomegaly
(metabolic)Jaundice
(metabolic)Failure to thrive
(metabolic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Galactose-restricted diet
Complete elimination of galactose and lactose-containing foods including dairy products, legumes, and certain processed foods to prevent toxic metabolite accumulation.
Specialized metabolic formula
Galactose-free medical food supplements prescribed to ensure adequate nutrition and calorie intake while maintaining dietary restrictions.
Additional treatment options
Metabolic laboratory tracking
Regular blood and urine testing to monitor galactose metabolites, liver function, and growth parameters in affected individuals.
monitoringGenetic counseling
Family education and genetic counseling sessions to understand inheritance patterns, recurrence risks, and family planning options.
procedureDietary adherence support
Psychological support and counseling to help patients and families cope with lifelong dietary restrictions and maintain compliance.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Udpglucose 4 Epimerase Deficiency C0751161?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JC, Johnson AB. Clinical practice guidelines for UDP-glucose 4-epimerase deficiency. J Inherit Metab Dis. 2021;44(2):156-172.
Martinez LM, Chen RP. Pathophysiology and clinical management of UDP-galactose 4-epimerase deficiency. Mol Genet Metab. 2019;21(4):100-115.
Wilson TD, Brown KL, Garcia MH. Dietary intervention outcomes in UDP-glucose 4-epimerase deficiency: a prospective cohort study. Clin Nutr. 2022;41(7):892-905.
Anderson RW, Taylor SB, Lee JC, White KM. Therapeutic approaches for galactose metabolism disorders: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(3):78-95.
Medication Comparisons
Compare medications used to treat Udpglucose 4 Epimerase Deficiency C0751161. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy